摘要
目的探讨清热解毒法联合新辅助化疗治疗乳腺癌的临床疗效及对患者免疫功能和生活质量的影响。方法选取经病理组织学检查确诊的TNM分期Ⅱ～Ⅲ期女性乳腺癌患者84例,应用随机数字表法分为联合组与对照组,每组42例。对照组给予AC序贯T新辅助化疗方案(环磷酰胺600 mg/m^2、阿霉素60 mg/m^2静滴,第1天,3周为1个周期,治疗4个周期后改为多西他赛75 mg/m^2静脉滴注1 h,3周为1个周期,治疗4个周期)。联合组在新辅助化疗基础上联合应用清热解毒方,每个治疗周期连服2周,连续治疗8个周期。2组化疗过程中密切监测患者的血常规,及时给予粒细胞集落刺激因子静脉滴注。统计2组近期疗效,观察2组治疗前后中医症状评分、免疫功能(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+、NK细胞)、Karnofsky功能状态评分(KPS评分)变化情况,记录2组不良反应发生情况。结果联合组近期临床总有效率为92.86%,明显高于对照组的85.71%(P<0.05)。2组治疗后中医症状评分均明显降低(P均<0.05),且联合组明显低于对照组(P<0.05)。治疗后,对照组CD3^+、CD4^+均明显低于治疗前(P均<0.05);联合组CD3^+、CD4^+及CD4^+/CD8^+均明显高于治疗前及对照组(P均<0.05),而CD8^+明显低于治疗前及对照组(P均<0.05);2组治疗前后NK细胞比例均无明显变化(P均>0.05)。2组治疗后KPS评分均明显升高(P均<0.05),且联合组明显高于对照组(P<0.05)。联合组血小板减少、恶心呕吐、心脏毒性、脱发、白细胞减少以及中性粒细胞减少发生率均明显低于对照组(P均<0.05)。结论清热解毒法联合新辅助化疗治疗乳腺癌近期疗效显著,能够明显缓解患者临床症状,改善免疫功能,减少不良反应,提高患者生存质量。
Objective It is to investigate the clinical efficacy of Qingrejiedu therpay combined with neoadjuvant chemotherapy in the treatment of breast cancer and its impact on immune function and quality of life. Methods Eighty-four female patients with stage TNM stage Ⅱ~Ⅲ breast cancer diagnosed by histopathological examination were enrolled and divided into the combined group and the control group by random number table, 42 cases in each group. The control group received AC sequential T neoadjuvant chemotherapy(cyclophosphamide 600 mg/m^2, doxorubicin 60 mg/m^2 by intravenous infusion, the first day, 3 weeks for 1 cycle, after treatment for 4 cycles, changed to docetaxel 75 mg/m^2 by intravenous infusion for 1 h, 3 weeks for 1 cycle, treatment for 4 cycles). The combined group was combined with Qingrejiedu drugs on the basis of neoadjuvant chemotherapy. Each treatment cycle was continued for 2 weeks and continuous treatment for 8 cycles. The blood routine of the patients was closely monitored during the chemotherapy, and the granulocyte colony-stimulating factor was intravenously infused in time. The short-term efficacy of the two groups was analyzed. The changes of TCM symptom scores, immune function(CD3^+, CD4^+, CD8^+, CD4^+/CD8^+, NK cells) and Karnofsky functional status score(KPS score) were observed before and after treatment. The incidence of adverse reactions in the two groups was recorded. Results The total clinical effective rate of the combined group was 92.86%, which was significantly higher than that of the control group(85.71%)(P<0.05). The scores of TCM symptoms in the two groups were significantly lower(P<0.05), and the combination group was significantly lower than the control group(P<0.05). After treatment, the CD3^+ and CD4^+ in the control group were significantly lower than those before treatment(P<0.05). The CD3^+, CD4^+ and CD4^+/CD8^+ in the combined group were significantly higher while CD8^+ was significantly lower than the pre-treatment and control groups(P<0.05). There was no significant
作者
施晓丽
谢俊
SHI Xiaoli;XIE Jun(Shiyan Renmin Hospital,Affiliated People's Hospital of Hubei Medical College,Shiyan 442000,Hubei,China)
出处
《现代中西医结合杂志》
CAS
2019年第12期1288-1291,1295,共5页
Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词
乳腺癌
新辅助化疗
免疫功能
生存质量
breast cancer
neoadjuvant chemotherapy
immune function
quality of life
